# Effect of Quetiapine on Negative Symptoms and Cognition

> **NCT00305422** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine fumarate
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00305422
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2009-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305422, "Effect of Quetiapine on Negative Symptoms and Cognition". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00305422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*